Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1%.20-09-2023
20-09-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives EIR for the formulation manufacturing facility at SEZ 2, Ahmedabad19-09-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Update on acquisition18-09-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation17-09-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day.15-09-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives EIR for the injectables manufacturing facility at Zydus Biotech Park, Ahmedabad.13-09-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The management of the Company will meet the investors in Singapore and Hong Kong between September 18 to September 20, 2023 in the form of an Non Deal Road Show. This will include both one-on-one meetings as well as group meetings.13-09-2023
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under Reg 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201511-09-2023
Zydus Lifesciences Ltd - 532321 - Incorporation Of Wholly Owned Subsidiary Company
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (the "Listing Regulations") in respect of incorporation of wholly owned subsidiary company.08-09-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Erythromycin Tablets USP, 250 mg and 500 mg.01-09-2023